NVN Liquidation Inc (NOVNQ)

[barnyarddog]

November 09, 2021 Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19

“These preclinical data support and further strengthen the rationale behind developing SB019 as a potential intranasal therapeutic against COVID-19. Through engagement with the Coronavirus Treatment Acceleration Program, or CTAP, we have made the FDA aware of our SB019 program and our intent to submit an IND. We remain focused on the next steps to submit an IND and initiate a Phase 1 study in humans no later than the second quarter of 2022,” commented Paula Brown Stafford, President and Chief Executive Officer of Novan.
https://novan.gcs-web.com/news-releases/news-release-details/novan-announces-favorable-preclinical-safety-data-and-intent

June 10, 2021
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
https://novan.gcs-web.com/news-releases/news-release-details/novan-announces-positive-preclinical-data-sb019-covid-19-anti